Helen Goergen

2.8k total citations
41 papers, 1.1k citations indexed

About

Helen Goergen is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Goergen has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pathology and Forensic Medicine, 21 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Goergen's work include Lymphoma Diagnosis and Treatment (36 papers), Lung Cancer Treatments and Mutations (20 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Helen Goergen is often cited by papers focused on Lymphoma Diagnosis and Treatment (36 papers), Lung Cancer Treatments and Mutations (20 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Helen Goergen collaborates with scholars based in Germany, Switzerland and Austria. Helen Goergen's co-authors include Andreas Engert, Peter Borchmann, Michael Fuchs, Volker Diehl, Karolin Behringer, Stefanie Kreissl, Bastian von Tresckow, Stephanie Sasse, Dennis A. Eichenauer and Julia Meißner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Helen Goergen

39 papers receiving 1.1k citations

Peers

Countries citing papers authored by Helen Goergen

Since Specialization

Citations

This map shows the geographic impact of Helen Goergen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Goergen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Goergen more than expected).

Fields of papers citing papers by Helen Goergen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Goergen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Goergen. The network helps show where Helen Goergen may publish in the future.

Co-authorship network of co-authors of Helen Goergen

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Goergen. A scholar is included among the top collaborators of Helen Goergen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Goergen. Helen Goergen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Christian Baues, Helen Goergen, Michael Fuchs, Johannes Rosenbrock, Eren Celik, Hans Theodor Eich, Carsten Kobe, Conrad‐Amadeus Voltin, Andreas Engert, Peter Borchmann, Simone Marnitz	6
2	Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group 2021 ·Leukemia ·(unknown), Helen Goergen, Stefanie Kreissl, Annette Plütschow, (unknown), Stephan Mathas, Julia Meißner, Martin Sökler, Max S. Topp, Vladan Vučinić, Andreas Zimmermann, Bastian von Tresckow, Michael Fuchs, Andreas Engert, Peter Borchmann, Dennis A. Eichenauer	18
3	PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study 2021 ·Annals of Oncology ·Dennis A. Eichenauer, Stefanie Kreissl, (unknown), Christian Baues, Carsten Kobe, (unknown), Helen Goergen, Michael Fuchs, Sylvia Hartmann, Bastian von Tresckow, Andreas Engert, Peter Borchmann	13
4	The interplay between cancer-related fatigue and functional health in Hodgkin lymphoma survivors. 2020 ·Health Psychology ·(unknown), Horst Müller, Helen Goergen, Stefanie Kreissl, Peter Borchmann, Axel Mayer	3
5	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group 2020 ·Journal of Clinical Oncology ·Stefanie Kreissl, Horst Müller, Helen Goergen, Julia Meißner, Max S. Topp, Martin Sökler, Jana Marková, Jürg Bernhard, Richard Greil, Bastian von Tresckow, Karolin Behringer, (unknown), Hans‐Henning Flechtner, (unknown), Michael Fuchs, Andreas Engert, Volker Diehl, Peter Borchmann	35
6	Consolidating Involved Field Radiotherapy Prevents Early and Local Recurrences in Early Stage Hodgkin Lymphoma 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Christian Baues, Helen Goergen, Michael Fuchs, Carsten Kobe, Markus Dietlein, Johannes Rosenbrock, (unknown), Hans‐Theodor Eich, (unknown), R. Semrau, Peter Borchmann, Andreas Engert, Simone Marnitz	2
7	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) 2018 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·(unknown), Alexander Fosså, Helen Goergen, Peter Kamper, Sirpa Leppä, Daniel Molin, Julia Meißner, Erika Ritter, Jacob Haaber Christensen, Martin Hutchings, Martin Fuchs, Andreas Engert, Peter Borchmann, (unknown)	0
8	Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18 2018 ·Annals of Oncology ·Conrad‐Amadeus Voltin, Helen Goergen, Christian Baues, Michael Fuchs, Jasmin Mettler, Stefanie Kreissl, (unknown), Bernd Klaeser, Alden A. Moccia, Alexander Drzezga, Andreas Engert, Peter Borchmann, Markus Dietlein, Carsten Kobe	33
9	Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials 2018 ·The Lancet Haematology ·Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, Paul J. Bröckelmann, Thomas Pabst, Michael Fridrik, Mathias Rummel, Wolfram Jung, (unknown), Stephanie Sasse, (unknown), Christian Baues, Volker Diehl, Andreas Engert, Peter Borchmann	32
10	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) 2018 ·Blood ·(unknown), Alexander Fosså, Helen Goergen, Peter Kamper, Sirpa Leppä, Daniel Molin, Julia Meißner, (unknown), Jacob Haaber Christensen, Martin Hutchings, Michael Fuchs, Andreas Engert, Carsten Kobe, Peter Borchmann	14
11	PATIENT PREFERENCES - SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT-ASSOCIATED BURDEN AND SIDE EFFECTS 2016 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·(unknown), Helen Goergen, H. Mueller, (unknown), Stefanie Kreissl, Martin Fuchs, Andreas Engert, Peter Borchmann, Karolin Behringer	3
12	Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group 2016 ·The Lancet Oncology ·Stefanie Kreissl, Horst Mueller, Helen Goergen, Axel Mayer, Corinne Brillant, Karolin Behringer, Teresa Halbsguth, Felicitas Hitz, Martin Soekler, Oluwatoyin Shonukan, Jens Ulrich Rueffer, Hans‐Henning Flechtner, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann	69
13	Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials 2016 ·Blood ·Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, (unknown), Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann	65
14	An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma 2013 ·Annals of Oncology ·Annette E. Hay, Beate Klimm, Bingshu E. Chen, Helen Goergen, Lois E. Shepherd, Michael Fuchs, Mary Gospodarowicz, Peter Borchmann, Joseph M. Connors, Jana Marková, Michael Crump, Andreas Lohri, Jane N. Winter, Bernd Dörken, R. Pearcey, Volker Diehl, Sandra J. Horning, Hans Theodor Eich, Andreas Engert, Ralph M. Meyer	27
15	Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions 2013 ·Annals of Oncology ·Beate Klimm, Helen Goergen, Michael Fuchs, Bastian von Tresckow, Boris Böll, Julia Meißner, (unknown), Volker Diehl, Hans Theodor Eich, Andreas Engert, Peter Borchmann	48
16	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma 2013 ·Leukemia & lymphoma ·Stephanie Sasse, Achim Rothe, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Stephan Kreher, Ulrich Jäger, Christopher Bangard, Georg Kuhnert, Boris Böll, Bastian von Tresckow, Andreas Engert	33
17	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience 2012 ·Blood ·Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, (unknown), Sebastian Theurich, Peter Borchmann, Andreas Engert	60
18	Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial 2012 ·Annals of Oncology ·Karolin Behringer, Indra Thielen, Horst Mueller, Helen Goergen, (unknown), Johannes Rosenbrock, Teresa Halbsguth, Dennis A. Eichenauer, Michael Fuchs, Katrin S. Reiners, (unknown), Katrin van der Ven, (unknown), Michael von Wolff, Volker Diehl, Andreas Engert, Peter Borchmann	63
19	Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone 2012 ·Blood ·Annette E. Hay, Beate Klimm, Bingshu E. Chen, Helen Goergen, Lois E. Shepherd, Michael Fuchs, Mary Gospodarowicz, Peter Borchmann, Joseph M. Connors, Jana Marková, Michael Crump, Andreas Lohri, Jane N. Winter, Bernd Dörken, R. Pearcey, Volker Diehl, Sandra J. Horning, Hans Theodor Eich, Andreas Engert, Ralph M. Meyer	6
20	Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. 2009 ·Blood ·Peter Borchmann, Volker Diehl, Helen Goergen, Horst Mueller, R.P. Mueller, Hans Theodor Eich, Hans Konrad Mueller‐Hermelink, Richard Herrmann, Jana Marková, Anthony D. Ho, Wolfgang Hiddemann, Bernd Doerken, Richard Greil, Andreas Engert	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact